-BPL has signed an agreement with a global company (Fortune500) to collaborate in the development of a new protein-based drug candidate.
According to the agreement, BPL will develop a bacterial fermentation, refolding process,
purification and formulation as well as the related analytical testing methods.
For this project, BPL will utilize its know-how and experience in recombinant protein expression in bacterial systems, purification and product formulation.
-BPL has signed an agreement with US based company for the development and production of series of enzymes and their immobilization to solid matrices. BPL will utilize its know-how and experience in recomninant enzyme expression in bacterial systems, purification and product formulation.
-BPL is relocating to a new facility in Yavne- 15 Nahal Snir st. The facility, designed and constructed specially according to BPL's plans and requirements, will be ready by ebd December 2017. BPL will start operation in the new facility by beginning January 2018.
Mr. Meir Azulay
MSc of Biochemistry from Hebrew University, 18 years at Interpharm, subsidiary of Serono (currently Merck-Serono) in various management positions (company closed manufacturing facility at end 2004). Production manager (protein purification under GMP conditions). Process development manager- transfer of process from R&D to production. Responsibility for Technology Transfer of different products and processes from and to Interpharm. Coordinating registration of secondary sites (SBC for manufacturing of Rebif).Seven years founder, owner and CEO of Protein-Production Services (PPS)- a privately held CRO/CMO
BPL Biologics 19 Hidekel st. Yavne POB 13240 8122614 Israel Tel: +972.76.548.8118 US: +973.723.9000